Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4076440 | 0.96 | ITGB3 (0.42) | CA1CA2ITGB3ITGA2BSIGMAR1 | |
| SCHEMBL1743025 | 0.91 | CYP4A11 (0.39) | SMN1; SMN2HTR1AHTR7 | |
| SCHEMBL2925326 | 0.82 | CNR1 (0.42) | HPGDHTTSMN1; SMN2 | |
| SCHEMBL1744284 | 0.82 | LMNA (0.54) | CA1CA2ITGB3ITGA2B | |
| SCHEMBL3474501 | 0.80 | TDP1 (0.47) | CA1CA2HPGDHTTSMN1; SMN2 | |
| SCHEMBL22402873 | 0.80 | TDP1 (0.47) | CA1CA2HPGDHTTSMN1; SMN2 | |
| SCHEMBL4190503 | 0.79 | KMT2A (0.37) | ITGB3ITGA2BHRH3HTR1AHTR7 | |
| SCHEMBL4186571 | 0.79 | KMT2A (0.37) | ITGB3ITGA2BHRH3HTR1AHTR7 | |
| SCHEMBL11914021 | 0.79 | HTR1A (0.49) | CA1CA2HPGDHTTHTR1A | |
| SCHEMBL31502348 | 0.78 | NAAA (0.38) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8933021-B2 | Insulin derivative | NOVO NORDISK A/S (DK) | 2015-01-13 | — | — | US | disclosed |
| US-8796205-B2 | Insulin derivative | NOVO NORDISK A/S (DK) | 2014-08-05 | — | — | US | disclosed |
| US-20090239785-A1 | Insulin Derivative | NOVO NORDISK A/S (DK) | 2009-09-24 | — | — | US | disclosed |
| EP-2015770-A2 | INSULIN DERIVATIVE | Novo Nordisk A/S (DK) | 2009-01-21 | — | — | EP | disclosed |
| WO-2007128817-A2 | INSULIN DERIVATIVE | NOVO NORDISK A/S (DK) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239785-A1 | Insulin Derivative | IAPP, INSR, GPR119 | CA1 3889/4885CA2 1248/4885ITGB3 4146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.